Successful treatment of Kaposiform hemangioendothelioma with everolimus.

Abstract

There is currently no consensus on the second-line management of Kaposiform hemangioendothelioma (KHE) that was resistant to prednisolone and vincristine. We described an eight-year-old male with KHE in the right femur that was resistant to prednisolone, vincristine and propranolol. Everolimus, an inhibitor of mammalian target of rapamycin (mTOR) at the dosage of 0.1 mg/kg/day, successfully decreased the tumor size and controlled the symptoms. Everolimus should be further studied as an alternative agent to sirolimus in the management of KHE.

• Authors: Teruaki Uno, Shuichi Ito, Atsuko Nakazawa, Osamu Miyazaki, Tetsuya Mori, Keita Terashima
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 62 Issue 3 Pg. 536-8 (Mar 2015) ISSN: 1545-5017 [Electronic] United States
• PMID: 25306933 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2014 Wiley Periodicals, Inc.

Chemical References

• Immunosuppressive Agents
• Vincristine
• Everolimus
• Prednisolone
• Propranolol
• Sirolimus

Topics

• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Child
• Drug Resistance, Neoplasm (drug effects)
• Everolimus
• Hemangioendothelioma (drug therapy, pathology)
• Humans
• Immunosuppressive Agents (administration & dosage)
• Kasabach-Merritt Syndrome (drug therapy, pathology)
• Male
• Prednisolone (administration & dosage)
• Propranolol (administration & dosage)
• Sarcoma, Kaposi (drug therapy, pathology)
• Sirolimus (administration & dosage, analogs & derivatives)
• Vincristine (administration & dosage)